Mirum Pharmaceuticals (MIRM)
(Delayed Data from NSDQ)
$41.12 USD
+0.14 (0.34%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $41.12 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Brokerage Reports
0 items in cart
Mirum Pharmaceuticals, Inc. [MIRM]
Reports for Purchase
Showing records 1 - 20 ( 109 total )
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
LIVMARLI Now Approved for PFIC Patients Three Months and Older in the EU As Expected; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Chenodal NDA Filing For CTX In-line With 2Q24 Guidance
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
EASL Data Explores LIVMARLI''s Long-Term Efficacy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
CHMP Renders Positive Opinion For LIVMARLI in PFIC; First Volixibat Clinical Data in PSC and PBC This Month; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q Recap: LIVMARLI 1Q24 Net Sales Grew 47% vs. 1Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
LIVMARLI Is Now Reimbursed in Canada For ALGS; Two Volixibat Interim Analyses Expected in 1H24; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
FDA Approves LIVMARLI for PFIC; Model Updates Lead to Raising Our PT to $58
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q Recap: 2024 Global Net Product Sales Guidance Set to $310-$320M, But OpEx Higher Too; Reduce PT to $45
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q Preview and Model Updates for a 2024 Top Pick; Multiple Near-Term Catalysts Abound; Affirm Buy, $58 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Mirum Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department